VALITIC

Herzliya, Israel – September 04, 2026 -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) reported second-quarter fiscal 2026 revenue of US$5.25 million (CAD 7.3 million), a 25.06% decline from US$7.01 million in the same period last year, as shifting U.S. customs and tariff policy under the Trump administration disrupted sales.

Gross margin holds above 90% despite revenue drop

Gross profit fell 23.0% to US$4.769 million, but gross margin remained elevated at 90.8% for the three months ended June 30, 2026, up from 88.4% a year earlier. The company attributed the resilience to its direct-to-consumer model and disciplined cost structure at consumer wellness subsidiary B.I. Sky Global Ltd., which it owns 60%.